Practical Implementation of Oral HMAs in MDS/CMML: Safety, Monitoring, and Coordination
| Optimizing Hypomethylating Therapy in Myelodysplastic Syndromes This program focuses on optimizing the use of oral hypomethylating agents (HMAs) in myeloid malignancies, primarily high-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). A multidisciplinary panel of hematologists, transplant specialists, and an oncology nurse practitioner discusses real-world cases involving TP53-mutated MDS and proliferative CMML, both complicated by cytopenias, comorbidities, logistical challenges, and patient preferences. |
|
ADVERTISEMENT
|
|
Featured Video |
 |
| Practical Implementation of Oral HMAs in MDS/CMML: Safety, Monitoring, and Coordination Explore the differences between bispecific antibodies and CAR T-cell therapy, highlighting their unique benefits and administration processes. |
|